Measuring MMP-14 protein in blood exosomes to help detect colorectal cancer
Official title: Performance of Serum Matrix Metalloproteinase (MMP14) Assay as a Novel Biomarker for Colorectal Cancer Screening in Subjects From 50 to 74 Years Old Referred for Colonoscopy After Positive FIT
Run by CHU de Reims · NCT06955767 · Data updated 2026-11-12
This research tries to see if measuring MMP-14 in tiny blood particles called exosomes can help detect colorectal cancer in people with a positive FIT who are scheduled for colonoscopy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 650 (estimated) |
| Sponsor | CHU de Reims Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Reims) |
| Status | Recruiting |
| Started | April 2, 2026 |
| Main results expected | April 2, 2028 |
| Study ends | April 2, 2028 |
| Registry record updated | April 9, 2026 |
| Trial ID | NCT06955767 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a positive FIT result who are scheduled for a total colonoscopy under general anesthesia and who can provide informed consent are eligible.
✕Probably not a fit
People currently receiving chemotherapy, with another active or recently treated cancer (within five years), legally protected individuals, or those without a positive FIT would not be expected to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter cross-sectional interventional study recruiting adults with a positive fecal immunochemical test (FIT) who are booked for colonoscopy. After consent, two 5 mL blood tubes are drawn and plasma is processed, frozen, and sent to a central lab where exosomes are isolated and characterized and MMP-14 protein levels are measured. Results will compare MMP-14 levels between patients with and without colorectal lesions found at colonoscopy. The goal is to determine whether exosomal MMP-14 could serve as a blood-based marker to better triage FIT-positive patients.
Why it matters
Potential benefit: If successful, this marker could help reduce unnecessary follow-up colonoscopies by better identifying which FIT-positive patients are likely to have colorectal lesions.
How similar studies have gone: Early pilot data reported by the team found higher exosomal MMP-14 in colorectal cancer patients, so this approach has promising preliminary evidence but is not yet validated in large populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Individuals presenting for colonoscopy with a positive FIT result. * Positive fecal immunoassay requiring total colonoscopy under general anesthesia. * Persons having agreed to participate in the study (signed consent form) * Adults affiliated to a health insurance scheme. Exclusion criteria: * History of other cancer not in remission or in remission for less than five years (with the exception of cervical cancer or basal cell skin cancer treated with curative intent) * Patients undergoing chemotherapy * Legally protected individuals
Where it's running
-
Damien JOLLY
Reims, France Recruiting
Study contacts
- Study coordinator: Laurent RAMONT
- Email: lramont@chu-reims.fr
- Phone: 03 26 78 78 01
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BiP inhibitor BPR001-615 in colorectal adenocarcinoma
This study tests whether the BiP inhibitor BPR001-615 can affect cancer cells from colorectal adenocarcinoma, in patients who will have surgical removal of their tumor at Nice University Hospital.
-
VVD-133214 with Pembrolizumab in advanced colorectal cancer
This study tests whether adding VVD-133214 to pembrolizumab helps people with advanced colorectal cancer better than pembrolizumab alone.
-
Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread
This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.
-
Breath test to help detect gastrointestinal cancers early
A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.
-
TLR9-based immunotherapy for peritoneal cancer with ascites
This trial tests ACM-CpG injections into the abdomen to see if it’s safe and can help people with peritoneal metastases or malignant ascites from colorectal or appendiceal cancer.
-
Combining botensilimab and balstilimab after standard treatment for colorectal cancer
This phase 2 trial tests whether giving botensilimab and balstilimab after standard therapy can clear detectable ctDNA in adults with stage II/III colorectal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.